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The 1.8 A˚ resolution crystal structure of a conserved domain of the potential
Burkholderia pseudomallei antigen and trimeric autotransporter BPSL2063 is
presented as a structural vaccinology target for melioidosis vaccine develop-
ment. Since BPSL2063 (1090 amino acids) hosts only one conserved domain,
and the expression/purification of the full-length protein proved to be
problematic, a domain-filtering library was generated using -lactamase as a
reporter gene to select further BPSL2063 domains. As a result, two domains (D1
and D2) were identified and produced in soluble form in Escherichia coli.
Furthermore, as a general tool, a genomic open reading frame-filtering library
from the B. pseudomallei genome was also constructed to facilitate the selection
of domain boundaries from the entire ORFeome. Such an approach allowed the
selection of three potential protein antigens that were also produced in soluble
form. The results imply the further development of ORF-filtering methods as
a tool in protein-based research to improve the selection and production of
soluble proteins or domains for downstream applications such as X-ray
crystallography.
1. Introduction
Melioidosis is a severe invasive disease caused by the Gram-
negative saprotrophic bacterium Burkholderia pseudomallei
(Cheng & Currie, 2005). Fatal clinical outcomes, coupled with
poor control by antibiotics, have led to the search for potential
vaccine components. In this context, a protein microarray
probed with immune sera from melioidosis seropositive and
recovery patients was formulated to identify potential anti-
gens (Felgner et al., 2009; Suwannasaen et al., 2011). One
seroreactive antigen identified by Felgner and coworkers is
BPSL2063, a 1090-residue trimeric autotransporter adhesin
(TAA; Felgner et al., 2009), also termed BpaB (Burkholderia
pseudomallei autotransporter B), shown to have a role in
adhesion and invasion (Campos et al., 2013). In fact, TAAs
are known immunogenic components; notably, the neisserial
adhesin A (NadA) TAA is one of the components of the
recently developed serogroup B meningococcal vaccine
4CMenB (Felgner et al., 2009; Giuliani et al., 2006).
As their name suggests, TAAs are trimeric, display adhesion-
like activities and, despite extensive sequence diversity,
contain conserved structural elements, as shown by the three-
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dimensional structures of several TAAs from diverse species
(Dautin & Bernstein, 2007; Edwards et al., 2010; Meng et al.,
2006, 2008; Nummelin et al., 2004; Szczesny et al., 2008).
TAAs, like classical autotransporters, comprise an N-terminal
passenger domain that can range from 200 to 3000 residues
and a C-terminal -domain that anchors the protein to the
outer membrane and facilitates the transport of the passenger
domain into the extracellular space (Dautin & Bernstein,
2007).
We are involved in a structural vaccinology project that
focuses on the crystal structure analyses of B. pseudomallei
seroreactive antigens as the foundations for computational
biology-guided epitope-discovery optimization to develop
immunogenic vaccine components (Felgner et al., 2009). In
this context, structure-based epitope-discovery optimization
has already proved successful for other B. pseudomallei anti-
gens (Gourlay et al., 2013, 2015; Lassaux et al., 2013; Malito &
Rappuoli, 2013). Here, we report the high-resolution crystal
structure analysis of the only conserved domain (residues 657–
992) from BPSL2063 detectable based on sequence consid-
erations.
As the crystallized domain (BPSL2063Xtal) covers about
one third of the full-length protein, and considering that
epitopes may be present in other regions of the protein, we
aimed to explore and design additional constructs covering the
whole length of the protein. Unfortunately, it was not possible
to produce the full-length form of BPSL2063 in bacterial cells
and, owing to a lack of sequence identity with other TAAs, the
design of additional domain constructs proved challenging. To
address this issue, we applied our platform of open reading
frame (ORF)-filtering analyses (D’Angelo et al., 2011; Di Niro
et al., 2010; Zacchi et al., 2003) to BPSL2063 using random
fragmentation of the gene and TEM-1 -lactamase as a folding
reporter coupled to next-generation sequencing (NGS). After
library sequencing, mapping reads help to select ORF frag-
ments that correspond to protein domains that are likely to
be soluble and correctly folded (D’Angelo et al., 2011). For
BPSL2063, the domain-filtered library identified two frag-
ments corresponding to residues 99–434 (BPSL2063D1) and
residues 718–1037 (BPSL2063D2), respectively, which were
cloned and expressed in soluble form in Escherichia coli and
purified for crystallization trials.
Finally, as a general tool for the identification of soluble
proteins/domains for downstream applications, including
three-dimensional structural studies, we report the construc-
tion of a B. pseudomallei genomic ORF-filtering library. This
approach, via subsequent functional enrichment analyses,
allowed us to identify three main protein functional categories
that were over-represented among the genes: cell-envelope
biogenesis, inorganic transport and nucleotide transport and
metabolism. Among these, three antigen genes (BPSL1801,
BPSL1626 and BPSL2520) that are the focus of our structural
vaccinology project were represented in the library; using the
boundaries identified by our filtering tool, constructs were
successfully designed leading to soluble proteins for further
applications. In fact, the crystal structure of one of these
antigens (BPSL2520) has been solved (to be published).
Our methods and results, although preliminary, imply that a
domain-filtering library approach may assist in the selection of
protein domain boundaries and may accelerate and improve
the steps leading to soluble protein production for down-
stream biochemical studies, such as crystallogenesis, where
protein stability and solubility are key issues.
2. Materials and methods
2.1. BPSL2063 domain-filtering library construction
The BPSL2063 gene encoding for amino acids 55–1090
(lacking the first 54 N-terminal residues corresponding to the
extended signal peptide region) was chemically synthesized
and cloned into pUC57 vector (GenScript). To facilitate
subsequent cloning, NdeI and BamHI restriction sites were
added to the 50 and 30 ends of the gene, respectively. Following
digestion, the fragment of 3111 nucleotides was collected.
Total BPSL2063 DNA (2 mg) was fragmented using a bench
sonicator (Covaris S2) with conditions optimized to obtain a
range of 200–800 bp fragments (duty cycle, 10%; intensity, 5.0;
cycles per burst, 200; duration, 2  60 s, total 120 s; mode,
frequency sweeping; temperature, 6C). BPSL2063 DNA
fragments were purified, blunt-ended using the Quick
Blunting Kit (New England Biosciences) and cloned into
pFILTER vector (D’Angelo et al., 2011). After ligation, the
BPSL2063 library was electroporated into E. coli BL21(DE3)
cells and plated on chloramphenicol plates supplemented with
ampicillin at the highest concentration (100 mg ml1). 106
bacterial cells were plated, and after overnight growth 104
colonies were obtained.
2.2. B. pseudomallei genomic ORF-filtering library
construction
B. pseudomallei strain K96243 genomic DNA (gDNA;
kindly supplied by Professor R. Titball, University of Exeter,
England) was fragmented by ultrasonication (Covaris S2; duty
cycle, 10%; intensity, 5.0; cycles per burst, 200; duration 2 
60 s, total 120 s; mode, frequency sweeping; temperature, 6C);
a range of 200–800 bp fragments was obtained. Fragments
were collected, purified, blunt-ended using the Quick Blunting
Kit (New England Biosciences) and cloned into pFILTER
vector using an EcoRV cloning site between a pelB leader
sequence and the mature -lactamase gene (D’Angelo et al.,
2011). After ligation, the B. pseudomallei genomic DNA
library was electroporated into E. coli BL21(DE3) cells and
plated on chloramphenicol plates supplemented with ampi-
cillin at the highest concentration (100 mg ml1). 5  107
bacterial cells were plated, and after overnight growth 105
colonies were obtained.
2.3. ORF- and domain-filtering library sequencing and
analysis
ORF fragments were excised from the pFILTER vector
by double digestion (BssHII and NheI) and 200 ng of DNA
fragments were purified using MinElute columns (Qiagen) in
order to remove shorter fragments. Ligation of the purified
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samples to specific adaptors and preparation of the sequencing
libraries was performed following the Rapid Library
preparation-method manual (Roche, 454 Titanium). DNA
libraries were quantified using a PicoGreen DNA Quantita-
tion Kit (Invitrogen) and checked for quality by capillary
electrophoresis (Agilent Bioanalyzer 2100 with High Sensi-
tivity DNA assay kit; Agilent Technologies). DNA libraries
were then amplified in emulsion following the Titanium LIB-L
em-PCR protocol (Roche). Reactions were recovered by
2-propanol emulsion breaking, and beads presenting clonally
amplified DNA fragments on their surface were enriched.
Each enriched sample was separately loaded onto one-eighth
of a PicoTiterPlate (PTP) and sequenced according to the 454
GS-FLX Titanium protocol.
In the first data-analysis pipeline, raw reads from both the
sequencing of the genomic ORF-filtering library and of the
domain-filtered BPSL2063 library were mapped against the
B. pseudomallei K96243 reference genome using the CLC
Genomics Workbench with default parameters. CLC mapping
files were exported as BAM files and the BEDTools package
was used to calculate the statistics for depth and coverage
(Quinlan & Hall, 2010). We performed the functional
enrichment test using the R software package to compute
Fisher test statistics (R Development Core Team, 2011).
In the second data-analysis pipeline, raw reads from the
sequencing of the genomic ORF-filtering library were
analysed using the recently developed NGS-TreX web inter-
face (http://www.ngs-trex.org), which has previously been
applied to the analysis of ORF-filtered genomic libraries
(D’Angelo et al., 2013; Boria et al., 2013).
2.4. Cloning, expression and purification of BPSL2063D1,
BPSL2063D2 and BPSL2063Xtal
BPSL2063D1 (residues 99–434), BPSL2063D2 (residues 712–
1037) and BPSL2063Xtal (residues 657–992) were amplified
from the chemically synthesized BPSL2063 gene cloned into
the pUC57 vector (GenScript) by PCR amplification using
Phusion DNA polymerase (Thermo Scientific) according
to standard protocols. For BPSL2063D1 and BPSL2063D2,
primers were designed according to pET151-D-TOPO
requirements (Life Technologies). For BPSL2063Xtal, primers
included BamHI and EcoRI restriction sites for cloning into
pET-21b (Novagen). Cloning regions are given in Table 1 and
primer details are reported in Supplementary Table S1.
Successful cloning and PCR fidelity were confirmed by DNA
sequencing (Eurofins Genomics).
The three domains were expressed as His-tag fusion
proteins in E. coli BL21(DE3) Star cells (Invitrogen) or Tuner
(DE3) cells (Novagen) in LB broth, inducing with 0.1 mM
IPTG at 18C overnight. Initial solubility tests were carried
out on 10 ml bacterial cultures using BugBuster Protein
Extraction Reagent (Merck) according to the maufacturer’s
instructions. Large-scale expression was carried out for
BPSL2063D2 and BPSL2063Xtal. Bacterial cells from a 0.25 l
culture were harvested and lysed in IMAC wash buffer 1 (see
above) containing one tablet of cOmplete Protease Inhibitor
Cocktail (Roche), lysozyme (0.20 mg ml1), DNases
(50 mg ml1) and 10 mM MgCl2. Cell lysis and purification
were as reported in the previous section. BPSL2063D2 was
further purified by size-exclusion chromatography on a
Superdex 200 (60/600) gel-filtration column (GE Healthcare)
pre-equilibrated with crystallization buffer (10 mM Tris pH
8.0). BPSL2063Xtal was exchanged into the same buffer using a
PD-10 desalting column (GE Healthcare). Protein purity was
judged by SDS–PAGE on a 12% NuPAGE Bis-Tris Precast
Gel with NuPAGE MES SDS Running Buffer (Life Tech-
nologies). Both protein samples were concentrated using
Amicon Ultra Centrifugal Filters (Millipore) for crystal-
lization trials.
2.5. Crystallization of BPSL2063Xtal
Crystallization trials for BPSL2063D2 (11.6 mg ml
1) and
BPSL2063Xtal (3.5 mg ml
1) were set up in 96-well Greiner
sitting-drop plates containing 100 ml crystallization solution
using an Oryx 8 robot (Douglas Instruments). Crystals of
BPSL2063Xtal grew overnight at 20
C in a 400 nl drop (70%
protein) in condition D1 [0.1 M malic acid, MES and Tris
(MMT) buffer pH 4.0, 25% PEG 1500] of the PACT Premier
screen (Molecular Dimensions). Crystals were immersed in
mother liquor containing an elevated concentration of PEG
1500 (40%) and flash-cooled in liquid nitrogen. Crystallization
experiments on BPSL2063D2 are ongoing; however, in light of
the proven necessity of proteolysis for the successful crystal-
lization of both BPSL2063Xtal and BpaA (Edwards et al., 2010)
as discussed later, controlled proteolysis of BPSL2063D2 may
be necessary.
2.6. BPSL2063Xtal data collection, structure determination
and refinement
Diffraction data were collected from a single crystal to
1.8 A˚ resolution (on beamline ID23-2 at the European
Synchrotron Radiation Facility, Grenoble, France; Supple-
mentary Table S3). Data were processed using XDS, assigned
to the monoclinic space group P21 and scaled using POINT-
LESS and SCALA, respectively, in the CCP4 suite (Evans,
2006; Kabsch, 2010). The three-dimensional structure of
BPSL2063Xtal was solved by molecular replacement with
MOLREP (Vagin & Teplyakov, 2010) using the structure of
the head domain of a TAA from B. pseudomallei strain 1710b
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Table 1
The cloning regions of the six genes/domains are illustrated in
comparison with the fragments that were represented in the
B. pseudomallei genomic ORF-filtering library.
Cloned residues and numbers in parentheses refer to the amino-acid sequence.
Gene Mapped region Cloned residues
BPSL1626 1883679 (1)–1884209 (176) 26–176
BPSL1801 2143929 (31)–2144346 (170) 21–171
BPSL2520 3035865 (9)–3036434 (198) 21–198
BPSL2063D1 2468275 (99)–2469280 (434) 99–434
BPSL2063D2 2470132 (718)–2471091 (1037) 712–1037
BPSL2063Xtal — 657–992
(BpaA; PDB entry 3laa) as a search model (67% sequence
identity over 153 residues; Edwards et al., 2010). The structure
was fitted to the generated electron-density maps using Coot
and was further refined using phenix.refine (Emsley &
Cowtan, 2004; Afonine et al., 2012). All data were refined to
satisfactory final Rgen and Rfree factors of 16.8 and 20.4%,
respectively, and the stereochemical parameters were checked
using MolProbity in the PHENIX platform (Supplementary
Table S4; Chen et al., 2010; Davis et al., 2007). Atomic co-
ordinates and structure factors have been deposited in the
Protein Data Bank (Berman et al., 2000) as PDB entry 4usx.
2.7. Cloning, expression and purification of BPSL1801,
BPSL1626 and BPSL2520
BPSL1801, BPSL1626 and BPSL2520, identified through
the B. pseudomallei genomic ORF-filtering library, were
cloned as N-terminal histidine-tag fusion proteins (Supple-
mentary Table S1) and expressed in E. coli BL21(DE3) Star
(BPSL1626), Rosetta (DE3)/pLysS (BPSL1801) or C41(DE3)/
pLysS (BPSL2520) cells in Luria–Bertani (LB) broth, inducing
with 0.5 mM IPTG, at 20C overnight. All fusion proteins were
purified from 0.5 l bacterial cultures, harvested, resuspended
in IMAC wash buffer 1 (50 mM potassium dihydrogen phos-
phate pH 8.0, 0.3M potassium chloride, 5 mM imidazole)
containing lysozyme (0.20 mg ml1), DNases (50 mg ml1) and
10 mM magnesium chloride. Bacteria were lysed using a Cell
Disruption System (Constant Systems) at 25 MPa. The soluble
fraction was obtained by centrifugation at 16 000 rev min1
for 20 min and was loaded onto a 5 ml Bio-Scale Mini Profinia
IMAC cartridge (Bio-Rad) pre-equilibrated with IMAC wash
buffer 1. Proteins were washed with IMAC wash buffer 2
containing 10 mM imidazole and were eluted with IMAC
elution buffer containing 250 mM imidazole.
3. Results
3.1. Primary structure analysis of BPSL2063
BPSL2063 (UniProt code Q63TA4) comprises 1090 amino
acids and is one of nine proteins belonging to the TAA protein
family involved in adhesion to host cells (Campos et al., 2013;
Lazar Adler et al., 2011). BPSL2063 contains an extended
signal peptide (ESPR; residues 1–54) typical of proteins
secreted by the type V secretion system, including TAAs (also
termed type Vc secretion-system proteins; Desvaux et al.,
2006; Henderson et al., 1998). BPSL2063 shares several short
conserved elements common to the first TAA characterized,
the Yersinia enterocolitica adhesin A (YadA): there are five
YadA stalk regions (PFAM PF05662) located between resi-
dues 478 and 989, a YadA-like head region (PF05658; residues
925–951) and a YadA C-terminal membrane-anchoring
domain (PF03895; residues 1015–1090).
3.2. Three-dimensional structure analyses of BPSL2063Xtal
BPSL2063Xtal was expressed, purified and crystallized as
described in x2 (Fig. 1, Supplementary Tables S1 and S2). The
1.8 A˚ resolution crystal structure of BPSL2063Xtal was solved
by molecular replacement using the structure of BpaA (PDB
entry 3laa; Edwards et al., 2010) as the search model and was
refined to convergence (Rgen = 16.8%, Rfree = 20.4%; Figs. 2a
and 2b and Supplementary Tables S3 and S4; see x2). There
are three BPSL2063Xtal chains (A, B and C; r.m.s.d. of 0.6–
0.68 A˚) present in the crystal asymmetric unit which interlock
to form the biologically relevant trimer (Figs. 2a and 2b).
Trimerization of TAAs is in fact essential for their transloca-
tion and function. Electron density was visible for residues
678–891, 678–890 and 677–892 in chains A, B and C, respec-
tively, corresponding to the absence of about 119 residues at
the C-terminus (19 residues derived from the vector),
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Figure 1
SDS–PAGE analysis of recombinant proteins. (a) Purified BPSL2063Xtal (lane 1) and BPSL2063D2 (lane 2). The top arrow indicates the full-length (FL)
form of the domains, whereas arrows P1 and P2 indicate two lower molecular-weight fragments observed for BPSL2063Xtal and BPSL2063D2,
respectively. (b) Expression and solubility tests of BPSL2063D1 showing the non-induced and induced cells (lanes 1 and 2, respectively), the total
bacterial extract (lane 3) and the soluble (lane 4) and insoluble (lane 5) fractions following chemical cell lysis and centrifugation. (c) Purified BPSL1626
(lane 1), BPSL1801 (lane 2) and BPSL2520 (lane 3). In all panels, molecular-weight markers (Genespin) are indicated on the left in kDa.
suggesting that BPSL2063Xtal had been subjected to proteo-
lysis during, and possibly prior to, crystallization. This is
consistent with an unlikely Matthews coefficient estimation
for a trimer of the entire construct (371 residues, of which 35
correspond to vector regions), and with SDS–PAGE analysis
of the purified protein, which highlighted a band at approxi-
mately 28 kDa (Fig. 1a). Controlled proteolysis was in fact
found to be essential for the crystallization of BpaA (Edwards
et al., 2010). Electron density was also absent for the first 33–
34 (16 vector residues) N-terminal residues (depending on the
chain), indicating conformational flexibility in this region.
3.3. The three-dimensional BPSL2063Xtal fold
Following structure-based homology analyses using the
PDBeFold server (http://www.ebi.ac.uk/msd-srv/ssm/), as
expected, the BPSL2063Xtal chain was found to be structurally
closely related to two other TAAs: BpaA (the search model;
r.m.s.d. of 0.92 A˚; 60.9% sequence identity) and a fragment
(K9; residues 1049–1304) from the Salmonella enterica TAA
SadA (PDB entry 2yo1; r.m.s.d. of 1.35 A˚; 33.2% sequence
identity; Edwards et al., 2010; Hartmann et al., 2012). (See Fig.
2c for a structural comparison of BPSL2063Xtal with BpaA.)
BPSL2063Xtal contains two YadA stalk regions (residues
682–699 and 829–852) and a YadA-like head region (residues
765–792; not predicted by PFAM), which forms a left-handed
parallel -roll. Structural comparisons between BPSL2063Xtal
and BpaA were made (Fig. 2c). In contrast to the N-terminus
of BpaA, which commences with a coiled coil, each
BPSL2063Xtal monomer begins with a so-called ‘neck’ region
(from the N-terminal residue to Asn695) that immediately
precedes the first YadA-like stalk. According to domain
annotation of the TAA nomenclature using the Bioinformatics
Toolkit available from the Max Planck Institute (http://
toolkit.tuebingen.mpg.de/dataa/), this region typically
connects -structured domains to coiled coils in the N- to
C-terminal direction only (Szczesny & Lupas, 2008). The
BPSL2063Xtal neck region is stabilized by several inter-
molecular hydrogen bonds and a salt bridge formed between
His682 ND1 in one chain and Asp692 OD1 and OD2 in the
adjacent chain.
The neck is followed by a -helix–-turn and -turn–-helix
motif. -Helix 1 partially superimposes with -helix 1 from
BpaA and is followed by a -turn (1–
2) absent in BpaA that is in turn
followed by a second -turn (3–4)
present in BpaA and -helix 2 (Fig. 2c).
-Helix 2 is followed by -strand 5 that
represents the first strand in a five-
stranded -sheet composed of three
-strands (6, 7 and 10) from the
adjacent chain and a fifth strand (11)
from the same monomer. This region
encompasses the so-called YadA-like
head motif (-strands 3 and 4; residues
765–792) (Figs. 2a and 2b). Between 7
and 10, the polypeptide chain deviates
and extends across the back of the
trimer to form a -turn (8–9). The
polypeptide deviates to form a second
neck connector domain and a C-term-
inal -helix (3). 3 contributed by each
chain intertwine to form a left-handed
coiled coil that contains a leucine zipper
formed between Leu852, Leu862 and
Leu869 and their equivalent residues in
the other chains. There is a short gap in
the electron density after residue 875 or
878 (chain C), followed by a -turn
(12–13) in chains A and C (non-
structured in chain B) that build the
C-terminus.
Several sequence motifs common to
TAA members are present in
BPSL2063Xtal, namely (i) the NSVAIG
TAA structural motif present in the
YadA head domain (residues 765–792)
of BPSL2063Xtal that mediates collagen
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Figure 2
Three-dimensional structure of the BPSL2063Xtal trimer. (a) Secondary-structure cartoon
representation of the three BPSL2063Xtal chains present in the crystal asymmetric unit. Chains
A, B and C are shown in blue, green and red, respectively. The N- and C-termini are labelled. (b)
Secondary-structure cartoon representation of BPSL2063Xtal chain A coloured according to
secondary-structure element, with -helices, -strands and unstructured regions coloured red,
yellow and green, respectively. (c) Secondary-structure cartoon representation of chain A from
BpaA (red), residues 1180–1336 of chain A from the K9 fragment of SadA (green; PDB entry 1y01)
and chain C from BPSL2063Xtal (blue), indicating the N- and C-termini of BPSL2063Xtal and the
three main regions of structural diversity in shaded ovals. All panels were generated using PyMOL.
binding in YadA (Nummelin et al., 2004), (ii) a HANS
connector motif, (iii) an FGG motif that is typically followed
by a GAxY motif, although BPSL2063Xtal does not conform to
this signature, and (iv) a HIN2 (FxG) motif. The first structural
representation of the HIN2 motif was proposed in the BpaA
structure, although a five-residue gap in the electron density
was observed (Edwards et al., 2010). In BPSL2063Xtal the
electron density is continuous and a -turn (comprising
-strands 8 and 9) is present. Based on structural analyses of
the BPSL2063Xtal structure, we may deduce that such struc-
tural differences are a consequence of how the BpaA
construct was designed. As 3 in BpaA is truncated, this
results in loss of the hydrogen bonds that stabilize this -turn.
Therefore, we propose the HIN2 motif from BPSL2063Xtal as
the real first representative structure of this motif.
3.4. Construction of a BPSL2063 domain-filtering library and
sequence analysis
Given the inability to express full-length BPSL2063 within
the 1090-residue protein, we constructed a domain-filtering
library (see x2) to identify potential soluble domains. 454 GS-
FLX Titanium sequencing was performed on filtered frag-
ments, and 5922 mapping reads with an average length of
294 bp for a total of 1 746 066 nucleotides (corresponding to a
sequencing depth of 533) were obtained. Despite the
elevated sequencing depth, only two regions of the BPSL2063
gene were covered by mapping reads (base pairs 2 468 275 to
2 469 280 and 2 470 132 to 2 471 091), corresponding to
amino-acid residues 99–434 (BPSL2063D1) and 718–1037
(BPSL2063D2), respectively. The latter construct extends over
the BPSL2063Xtal cloning region; however, it is longer both at
the N- and C-termini.
3.5. Production of BPSL2063D1 and BPSL2063D2
The two regions encoding for BPSL2063D1 and
BPSL2063D2 were amplified from gDNA and cloned into
pET151/TOPO and expressed as N-terminally His-tagged
proteins in E. coli Tuner (DE3) cells (BPSL2063D1) or
BL21(DE3) Star cells (BPSL2063D2), as described in x2. For
BPSL2063D2, it was necessary to clone from residue 712
instead of 718 owing to the excessive GC content (75%) of
the nucleotide stretch that surrounds residue 718, which was
undesirable for PCR amplification. The solubility of
BPSL2063D1 (Fig. 1b) was evidently lower than that of
BPSL2063D2, in accordance with the fact that the latter was
represented to a greater extent in the domain-filtering library.
Protein corresponding to both constructs was purified from
the soluble fraction in yields of 1–2 mg (BPSL2063D1) and
8 mg (BPSL2063D2) per litre of bacterial culture (Fig. 1a). The
purity of BPSL2063D1 was poor and further attempts to
improve sample purity (e.g. size-exclusion chromatography or
the addition of detergent) resulted in insufficient yields;
optimization of the purification procedure will be necessary
for crystallization screening. BPSL2063D2 was exchanged into
10 mM Tris–HCl pH 8.0 and concentrated for crystallization
trials (see x2).
3.6. Construction of a B. pseudomallei genome ORF-filtering
library
In order to extend our search methods to allow the iden-
tification of potential soluble domains on a larger scale, we
applied our strategy based on the construction of an
ORFeome library from the B. pseudomallei genome. By
fragmenting a whole (intronless) genome into DNA fragments
of 200–800 bp (D’Angelo et al., 2011; Heger & Holm, 2003) it
is possible to create a library of fragments coding for potential
domains (or parts thereof). DNA fragments encoding well
folded protein domains, fused upstream of -lactamase, allow
the reporter enzyme to fold correctly and allow bacteria to
survive the selective pressure posed by the antibiotic. With this
aim, B. pseudomallei strain K96243 gDNA was fragmented,
cloned and filtered by plating
onto plates containing increasing
ampicillin concentrations. 107
bacterial cells were plated and,
after overnight growth, approxi-
mately 1% of the cells survived at
the highest ampicillin concentra-
tion, yielding a library with an
estimated size of 3  105 (Fig. 3).
The library size is estimated
assuming an unbiased selection of
real ORF fragments of 200–
800 bp in length. Nevertheless,
the real fragment distribution is
derived from a combination of
additional factors, including the
possibility of selecting some
spurious ORFs as well as the
negative selection of some real
ORFs owing to the inability of
their translated products to fold.
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Figure 3
Schematic overview of the main steps in the construction of the B. pseudomallei genomic ORF-filtering
library. 1, random fragmentation of genomic DNA. 2, gDNA fragment cloning into the pFILTER vector
and filtering using -lactamase as a folding reporter. 3, harvesting of E. coli transformants and DNA
extraction. 4, gDNA fragment recovery by amplification using specific primers linked to adaptors for
sequencing. 5, deep sequencing. 6, data analysis.
In order to fully classify ORF fragments present in the
surviving bacteria, they were rescued from filtering plates and
plasmid DNA was obtained. The inserts were cleaved by
restriction-enzyme digestion and subjected to Roche 454 FLX
Titanium sequencing as described in x2 (Fig. 3).
Reads were analyzed using two different data-analysis
pipelines: the first is highly conservative and allows the
detection of multiple highly represented domains in single
proteins; the second is less conservative and identifies single
domains with high sequencing depth covered by highly
focused reads. Based on the first pipeline analysis, sequences
were aligned with the reference B. pseudomallei genome
(accession Nos. NC_006351.1 and NC_006350.1) and a total of
96 231 mapping reads with an average length of 225 bp were
obtained, corresponding to 19 420 180 nucleotides. The
number of genes covered by mapping reads was 739 (chro-
mosome 1) and 540 (chromosome 2), with a total of 1279
ORFs being represented in the library (21.5% of the total BPS
genes; see Supplementary Tables S5 and S6). According to the
second data-analysis pipeline, NGS-TreX, a total of 1441
ORFs were covered by mapping reads, 161 of which had a
sequencing depth higher than 10 and only 67 of which had a
focus above 0.8 (see x2).
3.7. Functional enrichment analysis of genes represented in
the genomic ORF-filtering library
Although a sequencing depth of about 4 for the coding
portion of the genome was obtained, only one fifth of the
ORFs were covered by mapping reads and considered as
represented in the ORF-filtering library. On these bases, we
extended our analysis to determine whether the filtering
vector in this case had exerted a selection based not only on
the folding characteristics of the domains but also on features
deriving from ORF function or cellular localization. With this
aim, we performed a functional enrichment analysis based on
a Fisher test, and observed that the main functional categories
that were over-represented among the genes filtered out by
both pipelines were cell-envelope biogenesis (p-value  0.01);
inorganic transport (p-value  0.01) and nucleotide transport
and metabolism (p-value  0.05) (Supplementary Table S7).
Our results imply that for complex bacterial genomes such as
that of B. pseudomallei (two chromosomes, 7.2 Mb and 68%
GC content) the ORF-filtering vector favours the selection of
ORFs encoding for proteins that are potentially exposed on
the cell surface, such as those involved in transport mechan-
isms or located in the cell membrane. Thus, the extension of
the filtering power of our selection strategy to identify protein
domains that are located in the outer membrane may be useful
in the context of host–pathogen interaction studies and may
prompt the identification of antigens. A list of the most
represented ORFs in the genomic filtering library (depth >10
with both pipelines and focus >0.8 with the NGS-TreX pipe-
line), belonging to the three most enriched functional cate-
gories, is reported in Table 2. These genes and gene regions
covered by mapping reads can be considered to be good
candidates for further recombinant production and biochem-
ical analyses.
Proteins involved in transport and in cell-envelope
biogenesis often exhibit large, complex structures comprising
highly hydrophobic intermembrane regions together with
extracellular and intracellular domains. 5% of chromosome 1
genes and 7.2% of chromosome 2 genes represented in the
ORF-filtered library and covered by sequencing were longer
than 3000 bases, suggesting that they encode proteins larger
than 1000 amino acids. Given the lack of functional annota-
tions, construct design for recombinant protein production
may prove to be challenging and to be the rate-limiting step
for subsequent biochemical/structural analyses.
3.8. ORF-filtering library-guided antigen-construct design
and recombinant production
As previously mentioned, in the context of a structural
vaccinology project we are focusing on the crystal structure
analysis of potential antigens to be used for in silico-based
epitope-discovery optimization. A comparison of our list of
potential antigens [previously selected via bioinformatics,
transcriptomics (Professor X. Daura’s group, Universitat
Auto`noma de Barcelona, Spain) or protein microarrays
(Felgner et al., 2009)] with the list of genes represented in the
genomic ORF-filtered library enabled the design of constructs
for BPSL1626, BPSL1801 and BPSL2520. We selected three
genes having three different levels of mean sequencing depth
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Table 2
A list of the most represented ORFs in the B. pseudomallei genomic ORF-filtered library belonging to the three most enriched functional categories
(depth of >10 for both pipelines and focus >0.8 with the NGS-TreX pipeline).
Locus ID Strand Gene coverage Mean depth Focus Peak start Peak end Gene description
BPSL0466 + 1 54.3301 0.896 503530 504348 ABC-type metal ion-transport system, periplasmic
component/surface antigen
BPSL0882  0.248963 25.6933 0.889 1023539 1023839 Chromate-transport protein ChrA
BPSL2351 + 0.189685 16.2189 0.941 2843904 2844338 Nitric oxide reductase large subunit
BPSL0824  0.008 14 0.917 958876 958883 ABC-type metal ion-transport system, periplasmic
component/surface adhesin
BPSL3404  0.338836 12.7974 0.941 4042163 4042553 Na+/H+-antiporter NhaD and related arsenite permeases
BPSS0357 + 1 6146.87 0.994 499290 499841 Uncharacterized protein probably involved in high-affinity
Fe2+ transport
BPSS0404 + 0.194891 22.8577 0.857 547293 547560 Cytochrome c peroxidase
BPSL1866 + 0.213035 31.242 0.824 2219853 2220072 Dihydroorotate dehydrogenase
BPSL2199  0.850214 48.4648 0.856 2640323 2640919 Cell wall-associated hydrolases (invasion-associated proteins)
BPSS0418 + 0.133936 99.2331 0.984 578817 578980 Capsule polysaccharide export protein
but very high levels of gene coverage (>0.80). BPSL1626 is the
second top gene listed, with a very high mean sequencing
depth of 342.3 and a coverage of 1; BPSL1801 has a medium
mean sequencing depth of 29.8 and a coverage of 0.81, and
BPSL2520 has a low mean sequencing depth of 3 and a
coverage of 0.95 (Supplementary Table S5; see Supplementary
Fig. S1 for a plot of the reads mapped on the three selected
genes). Fragments identified by the genomic ORF-filtered
library corresponded to the full-length proteins, except for
BPSL1801 (from residue 31; Table 1). Signal peptides in
BPSL1626 and BPSL2520 were removed from the constructs
as being unfavourable for crystallization.
All proteins were successfully produced in soluble form as
N-terminally His-tagged species in E. coli (see x2). The yields
of soluble purified protein were approximately 20, 5 and
100 mg per litre of bacterial culture for BPSL1626, BPSL1801
and BPSL2520, respectively (Fig. 1c). BPSL2520 readily
yielded diffraction-quality crystals and its three-dimensional
structure has been solved via molecular-replacement methods
(to be published); BPSL1626 and BPSL1801 are undergoing
crystallization trials.
4. Discussion
In the search for suitable components for a melioidosis
vaccine, we have been exploring the surfaceome of
B. pseudomallei for the three-dimensional structures of
potential antigens. Here, we present the 1.8 A˚ resolution
crystal structure of a conserved YadA-like domain from the
potential antigen BPSL2063, which was recognized by anti-
bodies from patients that tested positive for B. pseudomallei
infection (Felgner et al., 2009). The crystal structure will serve
as the basis for the application of computational epitope-
prediction methods, which have already proved successful for
other B. pseudomallei antigens identified by Felgner and
coworkers (Felgner et al., 2009; Gaudesi et al., 2015; Gourlay et
al., 2013, 2015; Lassaux et al., 2013). Although sequence
conservation is limited among TAA members, they share
three-dimensional structural features. The overall fold of
BPSL2063Xtal reported here reflects that of other TAA
members, displaying the canonical elongated and tightly
intertwined trimeric assembly, and comprises classical TAA
modules such as the YadA head and neck motifs. It also
displays conserved short sequence motifs, such as the HIN2
motif with its FxG signature sequence. With regard to the
latter motif, BPSL2063Xtal presents a continuous model in
contrast to the five-residue gap in the electron density of
BpaA affecting this region (Edwards et al., 2010), thus
presenting the first fully representative structure of this motif.
Owing to the considerable size of BPSL2063 (1090 residues)
and the presence of just one conserved domain
(BPSL2063Xtal), the construction of additional domains
mapping the entire polypeptide proved to be difficult
(Edwards et al., 2010). To facilitate this search, we constructed
a single-gene domain-filtering library that allowed us to
identify two main domains (BPSL2063D1 and BPSL2063D2)
located at the N- and C-termini, respectively, which were
produced as recombinant His-tagged proteins in soluble form
for purification/crystallization trials. Notably, the majority of
BPSL2063Xtal is covered by BPSL2063D2.
The availability of a soluble/stable protein construct is often
the rate-limiting factor in macromolecular crystallography and
in protein-based research in general. It is estimated that only
30–40% of full-length proteins can be successfully expressed
and purified; this figure decreases to 20% for soluble
eukaryotic proteins (DiDonato et al., 2004; Gra¨slund et al.,
2008; Phizicky et al., 2003). In the case of BPSL2063, further to
the identification of domains within one protein through a
single-gene domain-filtering library, we aimed to develop a
high-throughput tool to identify soluble protein domains from
the entire protein repertoire of B. pseudomallei by generating
a genomic DNA ORF-filtering library for analysis by NGS.
By randomly fragmenting genomic DNA into 200–800 bp
fragments and fusing them with the folding reporter TEM-1
-lactamase, fragments that encode correctly folded/soluble
proteins/domains can be specifically selected (D’Angelo et al.,
2011; Di Niro et al., 2010; Zacchi et al., 2003). NGS mapping
reads obtained after genomic DNA library sequencing, and
data regarding fragments that encode for ORF regions,
provide unbiased information on the location of proteins/
domains that are likely to result in soluble products. Our
results imply that for complex bacterial genomes such as that
of B. pseudomallei (two chromosomes, 7.2 Mb and 68% GC
content), the ORF-filtering vector favours the selection of
ORFs encoding for proteins that are potentially exposed on
the cell surface, such as those involved in transport mechan-
isms or located in the cell membrane. Thus, the extension of
the filtering power of our selection strategy to identify outer
membrane-localized protein domains may be useful in the
context of host–pathogen interaction studies and may support
the identification of antigens. Soluble constructs were
produced for three potential antigens represented in the ORF-
filtered library. The structure of one such antigen (BPSL2520)
has been recently solved by our group (to be published).
Although we do not suggest that our approach will identify
domains that will necessarily yield viable crystals, as there
are numerous other biophysical factors that affect crystallo-
genesis, the identification of soluble/stable domains will
undoubtedly increase the probability of successful crystal
growth.
The advantage of our strategy that couples random genomic
DNA fragmentation to filtering includes the fact that it does
not require extensive analyses, gene-specific primer synthesis
or PCR amplifications. Furthermore, the collection created
consists of many different versions of each domain, each
differing by a few amino acids. Identified protein fragments
may find different applications, including functional studies,
structural studies, antibody generation, protein–substrate
binding analyses and domain shuffling for enzyme evolution.
The filtering approach applied here to the B. pseudomallei
genome could be applied to any other pathogen, leading to
more direct cloning, expression and purification of soluble
proteins/domains for any of the above applications, including
crystallogenesis. The filtering strategy can also integrate well
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with in silico-based reverse vaccinology (RV) approaches to
antigen discovery that rely heavily on successive antigen
production for immunological testing.
Once a library has been generated, it can be exploited as
a ‘universal reagent’, usually after the fragments have been
recloned into a phage-display context. Once displayed on
phage, fragments can be selected by using different targets.
For example, by using sera from pathogen-infected patients
the isolated fragments may allow the identification of bacterial
antigens/epitopes specifically recognized by host antibodies.
Conversely, interactome networks could be profiled by
isolating fragments encoding domains carrying specific
binding properties (e.g. the recognition of other proteins or
domains; Di Niro et al., 2010). Finally, when adequate probes
are available (Evans & Cravatt, 2006; Velappan et al., 2010),
the identification of domains showing specific enzymatic
activity could provide a simpler method to annotate genes
(and their assignment to specific metabolic pathways) on the
basis of determined function, rather than homology.
Acknowledgements
This project was supported by the Fondazione CARIPLO
(Progetto Vaccini, contract No. 2009-3577), joint funding
between the Fondazione CARIPLO and the Regione
Lombardia (Progetto PROVA, contract No. 42666248). LJG
was a recipient of Assegno di Ricerca (2012) from the
University of Milan.
References
Afonine, P. V., Grosse-Kunstleve, R. W., Echols, N., Headd, J. J.,
Moriarty, N. W., Mustyakimov, M., Terwilliger, T. C., Urzhumtsev,
A., Zwart, P. H. & Adams, P. D. (2012). Acta Cryst. D68, 352–367.
Berman, H. M., Westbrook, J., Feng, Z., Gilliland, G., Bhat, T. N.,
Weissig, H., Shindyalov, I. N. & Bourne, P. E. (2000). Nucleic Acids
Res. 28, 235–242.
Boria, I., Boatti, L., Pesole, G. & Mignone, F. (2013). BMC
Bioinformatics, 14, Suppl. 7, S10.
Campos, C. G., Byrd, M. S. & Cotter, P. A. (2013). Infect. Immun. 81,
2788–2799.
Chen, V. B., Arendall, W. B., Headd, J. J., Keedy, D. A., Immormino,
R. M., Kapral, G. J., Murray, L. W., Richardson, J. S. & Richardson,
D. C. (2010). Acta Cryst. D66, 12–21.
Cheng, A. C. & Currie, B. J. (2005). Clin. Microbiol. Rev. 18, 383–416.
D’Angelo, S., Mignone, F., Deantonio, C., Di Niro, R., Bordoni, R.,
Marzari, R., De Bellis, G., Not, T., Ferrara, F., Bradbury, A.,
Santoro, C. & Sblattero, D. (2013). Clin. Immunol. 148, 99–109.
D’Angelo, S., Velappan, N., Mignone, F., Santoro, C., Sblattero, D.,
Kiss, C. & Bradbury, A. R. (2011). BMCGenomics, 12, Suppl. 1, S5.
Dautin, N. & Bernstein, H. D. (2007). Annu. Rev. Microbiol. 61,
89–112.
Davis, I. W., Leaver-Fay, A., Chen, V. B., Block, J. N., Kapral, G. J.,
Wang, X., Murray, L. W., Arendall, W. B., Snoeyink, J., Richardson,
J. S. & Richardson, J. S. (2007). Nucleic Acids Res. 35, W375–W383.
Desvaux, M., Cooper, L. M., Filenko, N. A., Scott-Tucker, A., Turner,
S. M., Cole, J. A. & Henderson, I. R. (2006). FEMS Microbiol. Lett.
264, 22–30.
DiDonato, M., Deacon, A. M., Klock, H. E., McMullan, D. & Lesley,
S. A. (2004). J. Struct. Funct. Genomics, 5, 133–146.
Di Niro, R., Sulic, A. M., Mignone, F., D’Angelo, S., Bordoni, R.,
Iacono, M., Marzari, R., Gaiotto, T., Lavric, M., Bradbury, A. R.,
Biancone, L., Zevin-Sonkin, D., De Bellis, G., Santoro, C. &
Sblattero, D. (2010). Nucleic Acids Res. 38, e110.
Edwards, T. E., Phan, I., Abendroth, J., Dieterich, S. H., Masoudi, A.,
Guo, W., Hewitt, S. N., Kelley, A., Leibly, D., Brittnacher, M. J.,
Staker, B. L., Miller, S. I., Van Voorhis, W. C., Myler, P. J. & Stewart,
L. J. (2010). PLoS One, 5, e12803.
Emsley, P. & Cowtan, K. (2004). Acta Cryst. D60, 2126–2132.
Evans, M. J. & Cravatt, B. F. (2006). Chem. Rev. 106, 3279–
3301.
Evans, P. (2006). Acta Cryst. D62, 72–82.
Felgner, P. L. et al. (2009). Proc. Natl Acad. Sci. USA, 106, 13499–
13504.
Gaudesi, D., Peri, C., Quilici, G., Gori, A., Ferrer-Navarro, M.,
Conchillo-Sole, O., Thomas, R., Nithichanon, A., Lertmemongkol-
chai, G., Titball, R., Daura, X., Colombo, G. & Musco, G. (2015).
ACS Chem. Biol. 10, 803–812.
Giuliani, M. M. et al. (2006). Proc. Natl Acad. Sci. USA, 103, 10834–
10839.
Gourlay, L. J. et al. (2013). Chem. Biol. 20, 1147–1156.
Gourlay, L. J., Thomas, R. J., Peri, C., Conchillo-Sole´, O., Ferrer-
Navarro, M., Nithichanon, A., Vila, J., Daura, X., Lertmemong-
kolchai, G., Titball, R., Colombo, G. & Bolognesi, M. (2015). FEBS
J. 282, 1980–1997.
Gra¨slund, S. et al. (2008). Nature Methods, 5, 135–146.
Hartmann, M. D., Grin, I., Dunin-Horkawicz, S., Deiss, S., Linke, D.,
Lupas, A. N. & Hernandez Alvarez, B. (2012). Proc. Natl Acad. Sci.
USA, 109, 20907–20912.
Heger, A. & Holm, L. (2003). J. Mol. Biol. 328, 749–767.
Henderson, I. R., Navarro-Garcia, F. & Nataro, J. P. (1998). Trends
Microbiol. 6, 370–378.
Kabsch, W. (2010). Acta Cryst. D66, 133–144.
Lassaux, P., Peri, C., Ferrer-Navarro, M., Gourlay, L. J., Gori, A.,
Conchillo-Sole´, O., Rinchai, D., Lertmemongkolchai, G., Longhi,
R., Daura, X., Colombo, G. & Bolognesi, M. (2013). Structure, 21,
167–175.
Lazar Adler, N. R., Stevens, J. M., Stevens, M. P. & Galyov, E. E.
(2011). Front. Microbiol. 2, 151.
Malito, E. & Rappuoli, R. (2013). Chem. Biol. 20, 1205–1206.
Meng, G., St Geme, J. W. III & Waksman, G. (2008). J. Mol. Biol. 384,
824–836.
Meng, G., Surana, N. K., St Geme, J. W. & Waksman, G. (2006).
EMBO J. 25, 2297–2304.
Nummelin, H., Merckel, M. C., Leo, J. C., Lankinen, H., Skurnik, M.
& Goldman, A. (2004). EMBO J. 23, 701–711.
Phizicky, E., Bastiaens, P. I., Zhu, H., Snyder, M. & Fields, S. (2003).
Nature (London), 422, 208–215.
Quinlan, A. R. & Hall, I. M. (2010). Bioinformatics, 26, 841–842.
R Development Core Team (2011). R: A Language and Environment
for Statistical Computing. Vienna: The R Foundation for Statistical
Computing.
Suwannasaen, D., Mahawantung, J., Chaowagul, W., Limmathurot-
sakul, D., Felgner, P. L., Davies, H., Bancroft, G. J., Titball, R. W. &
Lertmemongkolchai, G. (2011). J. Infect. Dis. 203, 1002–1011.
Szczesny, P., Linke, D., Ursinus, A., Ba¨r, K., Schwarz, H., Riess, T. M.,
Kempf, V. A., Lupas, A. N., Martin, J. & Zeth, K. (2008). PLoS
Pathog. 4, e1000119.
Szczesny, P. & Lupas, A. (2008). Bioinformatics, 24, 1251–1256.
Vagin, A. & Teplyakov, A. (2010). Acta Cryst. D66, 22–25.
Velappan, N., Fisher, H. E., Pesavento, E., Chasteen, L., D’Angelo, S.,
Kiss, C., Longmire, M., Pavlik, P. & Bradbury, A. R. (2010). Nucleic
Acids Res. 38, e22.
Zacchi, P., Sblattero, D., Florian, F., Marzari, R. & Bradbury, A. R.
(2003). Genome Res. 13, 980–990.
research papers
Acta Cryst. (2015). D71, 2227–2235 Gourlay et al.  Burkholderia pseudomallei antigen BPSL2063 2235
